Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02992236 |
Recruitment Status :
Completed
First Posted : December 14, 2016
Results First Posted : August 9, 2019
Last Update Posted : August 9, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Renal Function Impairment in Healthy Volunteers | Drug: VAS203 Drug: Saline | Phase 1 |
Analysis of the effect of i.v. VAS203 on renal function and perfusion in healthy subjects.
Primary objective:
Possible adverse effect of VAS203 on the Renal Plasma Flow (RPF) and the Glomerular Filtration Rate (GFR) during and after 6 hours of constant-rate iv. infusion of 10 mg/kg VAS203.
Secondary objective:
To analyse the effects of VAS203 on
- filtration fraction
- hemodynamics (afferent and efferent resistance, intraglomerular pressure)
- markers of kidney injury and renal function
- systolic, mean and diastolic brachial blood pressure
- Plasma Pharmacokinetic of VAS203 and its first metabolite.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 16 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Other |
Official Title: | Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers |
Study Start Date : | August 2015 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | November 2016 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Infusion (6 hours) of Saline
|
Drug: Saline
Infusion of saline
Other Name: 0.9% sodium chloride |
Active Comparator: VAS203
Infusion (6 hours) of VAS203 (10 mg/kg)
|
Drug: VAS203
Infusion of NO-Synthase inhibitor VAS203
Other Name: Ronopterin |
- Renal Plasma Flow [ Time Frame: 0, 2h, 4h, 6h and 8 h after start of infusion ]Renal plasma flow measurement by para-Amino-Hippuric-Acid Clearance Method
- Glomerular Filtration Rate [ Time Frame: 0, 2h, 4h, 6h and 8 h after start of infusion ]by para-Amino-Hippuric Acid Clearance Method
- Serum Creatinine Concentration [ Time Frame: 0, 2h, 4h, 6h, 8h, 10h, 24h and 48h after start of infusion ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Informed consent in writing available.
- Willing and able to comply with all requirements of the study.
- Male, 18 and 45 years (inclusive).
- Subject has a body weight between 60 kg and 100 kg, extremes included.
- BMI 18 to 27 kg/m2.
- Non-smoker
- Serum creatinine within reference range (≤1.2 mg/dL) and Cockroft-Gault Clearance > 90 ml/min
- Good general health as judged by the Investigator, as determined by medical history, physical examination, vital signs (systolic and diastolic blood pressure and pulse rate) and clinical laboratory parameters (clinical chemistry, hematology, and urinalysis)
Exclusion Criteria:
- Clinically significant abnormalities in physical examination, vital signs or clinical laboratory parameters (according to the Investigator's judgment).
- Serum glutamate oxaloacetate transaminase or glutamate-pyruvate transaminase > 2-times above the upper limit of normal range.
- Subject with Cockcroft-Gault clearance < 90 ml/min.
- Clinically significant history of cardiovascular disease or any known present cardiovascular disease.
- History of clinically significant neurological, gastrointestinal, renal, hepatic, psychological, pulmonary, metabolic, endocrine, hematological, or other major disorders.
- Office blood pressure at screening higher than 160/100 mmHg, or lower than 95/55 mmHg.
- Office heart rate at screening after at least 5 minutes outside the range of 50- 99 beats per minute (inclusive).
- Concomitant use of OTC medication within 1 week prior to dosing, except use of paracetamol (up to 2 g/day).
- Participation in any other clinical study within 30 days prior to inclusion in this -

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02992236
Germany | |
Universitätsklinik Erlangen | |
Erlangen, Germany, 91054 |
Principal Investigator: | Roland E Schmieder, Prof. Dr. | Universitätsklinik Erlangen |
Responsible Party: | Vasopharm GmbH |
ClinicalTrials.gov Identifier: | NCT02992236 |
Other Study ID Numbers: |
VAS203/I/3/05 |
First Posted: | December 14, 2016 Key Record Dates |
Results First Posted: | August 9, 2019 |
Last Update Posted: | August 9, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |